Evidence map›Paper›PMID 42211151›Full record

ReviewJournal of lipid and atherosclerosis2026

Molecular and Genetic Aspects of Lipid Metabolism Disorders and Potential Targets for Gene Therapy.

Elvira R Akhmetzyanova, Anna V Timofeeva, Danil R Gallyamov, Albert A Rizvanov, Yana O Mukhamedshina

Abstract readReview
In one paragraph

Review in Journal of lipid and atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elvira R AkhmetzyanovaOpenLab Gene and Cell Technology, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.ORCID https://orcid.org/0000-0002-5751-6759
Anna V TimofeevaOpenLab Gene and Cell Technology, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.ORCID https://orcid.org/0000-0002-3393-6775
Danil R GallyamovOpenLab Gene and Cell Technology, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.ORCID https://orcid.org/0009-0004-4566-6268
Albert A RizvanovOpenLab Gene and Cell Technology, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.ORCID https://orcid.org/0000-0002-9427-5739
Yana O MukhamedshinaOpenLab Gene and Cell Technology, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.ORCID https://orcid.org/0000-0002-9435-340X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diseases associated with impaired lipid metabolism are major contributors to the rising global burden of cardiovascular disease. Over the past several decades, cardiovascular diseases have consistently remained the leading cause of mortality and disability worldwide. Many of these conditions are linked to mutations in genes encoding proteins that regulate lipid metabolism. At the same time, secondary lipid metabolism disorders can arise from unhealthy lifestyles and harmful habits that initiate pathological processes. Understanding the mechanisms underlying these processes is essential for developing new therapeutic strategies for both primary and secondary lipid metabolism disorders. The rapid advancement of innovative gene therapy approaches has introduced novel strategies for treating a wide range of diseases, and further progress in these technologies is expected to broaden the spectrum of target conditions. This review will examine potential therapeutic targets for lipid metabolism disorders and summarize existing gene therapy approaches.

Indexed as

CholesterolGene therapyHyperlipidemiaSiRNA

Identifiers

PMID42211151
PMCPMC13213238

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.